A Randomised, Repeat-dose, Placebo-controlled, Double-blind Study to Evaluate and Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder, When Administered Either in the Morning or in the Evening, in Male and Female Asthmatic subjects
Phase of Trial: Phase II
Latest Information Update: 12 Jan 2017
At a glance
- Drugs Vilanterol/fluticasone furoate (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 05 Sep 2012 Results presented at the 22nd Annual Congress of the European Respiratory Society.
- 11 May 2012 Actual patient number changed from 7 to 26 as reported by ClinicalTrials.gov.
- 13 Jan 2012 Actual patient number 7 added as reported by ClinicalTrials.gov.